India will roll out the indigenously developed HPV vaccine against cervical cancer for girls in the age group of 9–14 under the National Immunisation Programme by mid-2023. Developed by the Serum Institute of India, the quadrivalent vaccine called ‘Cervavac’, has a relatively lower price tag of Rs 200-400. India is dependent on foreign manufacturers for the vaccine, currently priced between Rs 3000-4000. It’s being described as a major breakthrough as India accounts for about a quarter of all cervical cancer cases & nearly a third of global cervical cancer deaths.
Anchor: Teena Jha
1. Dr. Manoj Sharma, Consultant, Clinical Oncology, Delhi State Cancer Institute
2. Dr. Kanika Sylonia, Consultant, Gynecologist & Obstetrician RML Hospital
Follow us on:
Subscribe to Sansad TV YouTube Channel: https://www.youtube.com/c/SansadTV
Visit Sansad TV website: https://sansadtv.nic.in/
FB-116, Parliament Library Building, Parliament House Complex, New Delhi 110001